Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 2
2014 2
2015 3
2016 5
2017 1
2018 4
2019 2
2020 3
2021 2
2023 7
2024 5
2025 8
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
Jabbour E, Kantarjian HM, Aldoss I, Montesinos P, Leonard JT, Gómez-Almaguer D, Baer MR, Gambacorti-Passerini C, McCloskey J, Minami Y, Papayannidis C, Rocha V, Rousselot P, Vachhani P, Wang ES, Wang B, Hennessy M, Vorog A, Patel N, Yeh T, Ribera JM. Jabbour E, et al. JAMA. 2024 Jun 4;331(21):1814-1823. doi: 10.1001/jama.2024.4783. JAMA. 2024. PMID: 38722621 Free PMC article. Clinical Trial.
From January 2019 to May 2022, eligible patients at 77 sites were randomized 2:1 to ponatinib (30 mg/d) or imatinib (600 mg/d) with reduced-intensity chemotherapy, followed by single-agent ponatinib or imatinib after the cycle 20 phase of the trial. The last date of …
From January 2019 to May 2022, eligible patients at 77 sites were randomized 2:1 to ponatinib (30 mg/d) or imatinib (600 mg/d) with r …
Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial.
Cortes J, Apperley J, Lomaia E, Moiraghi B, Undurraga Sutton M, Pavlovsky C, Chuah C, Sacha T, Lipton JH, Schiffer CA, McCloskey J, Hochhaus A, Rousselot P, Rosti G, de Lavallade H, Turkina A, Rojas C, Arthur CK, Maness L, Talpaz M, Mauro M, Hall T, Lu V, Srivastava S, Deininger M. Cortes J, et al. Blood. 2021 Nov 25;138(21):2042-2050. doi: 10.1182/blood.2021012082. Blood. 2021. PMID: 34407543 Free PMC article. Clinical Trial.
In PACE (Ponatinib Ph+ ALL and CML Evaluation), a phase 2 trial of ponatinib that included patients with chronic-phase chronic myeloid leukemia (CP-CML) resistant to multiple prior tyrosine kinase inhibitors (TKIs), ponatinib showed deep and durable responses …
In PACE (Ponatinib Ph+ ALL and CML Evaluation), a phase 2 trial of ponatinib that included patients with chronic-phase chronic …
Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia.
Jabbour E, DerSarkissian M, Duh MS, McCormick N, Cheng WY, McGarry LJ, Souroutzidis A, Huang H, O'Brien S, Ravandi F, Kantarjian HM. Jabbour E, et al. Clin Lymphoma Myeloma Leuk. 2018 Apr;18(4):257-265. doi: 10.1016/j.clml.2018.02.010. Epub 2018 Feb 17. Clin Lymphoma Myeloma Leuk. 2018. PMID: 29519619
Greater OS was observed with ponatinib compared with the pooled OS for earlier generation TKIs (2-year, 83% vs. 58%; 3-year, 79% vs. 50%). ...CONCLUSION: Ponatinib plus chemotherapy might be associated with better outcomes than chemotherapy with earlier generation T …
Greater OS was observed with ponatinib compared with the pooled OS for earlier generation TKIs (2-year, 83% vs. 58%; 3-year, 79% vs. …
The multi-tyrosine kinase inhibitor ponatinib for chronic myeloid leukemia: Real-world data.
Luciano L, Annunziata M, Attolico I, Di Raimondo F, Maggi A, Malato A, Martino B, Palmieri F, Pane F, Sgherza N, Specchia G. Luciano L, et al. Eur J Haematol. 2020 Jul;105(1):3-15. doi: 10.1111/ejh.13408. Epub 2020 Mar 15. Eur J Haematol. 2020. PMID: 32145037 Review.
This paper reviews the effectiveness, feasibility, and safety of ponatinib in the real-life clinical management of CML. Potential prognostic factors in identifying patients most likely to benefit from ponatinib treatment will be discussed, and case presentations ill …
This paper reviews the effectiveness, feasibility, and safety of ponatinib in the real-life clinical management of CML. Potential pro …
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial.
Jabbour E, Oehler VG, Koller PB, Jamy O, Lomaia E, Hunter AM, Uspenskaya O, Samarina S, Mukherjee S, Cortes JE, Baer MR, Zherebtsova V, Shuvaev V, Turkina A, Davydkin I, Guo H, Chen Z, Fu T, Jiang L, Wang C, Wang H, Yang D, Zhai Y, Kantarjian H. Jabbour E, et al. JAMA Oncol. 2025 Jan 1;11(1):28-35. doi: 10.1001/jamaoncol.2024.5157. JAMA Oncol. 2025. PMID: 39570620 Free PMC article. Clinical Trial.
A total of 15 of 26 patients with prior ponatinib treatment (58%; 95% CI, 36.9-76.6) achieved CCyR, and 11 of 30 (37%; 95% CI, 19.9-56.1) achieved MMR. ...CONCLUSIONS AND RELEVANCE: In this trial, olverembatinib had a favorable pharmacokinetic profile, was generally well t …
A total of 15 of 26 patients with prior ponatinib treatment (58%; 95% CI, 36.9-76.6) achieved CCyR, and 11 of 30 (37%; 95% CI, 19.9-5 …
Population Pharmacokinetic and Exposure-Response Analyses for Ponatinib in the Phase 3 PhALLCON Study.
Hanley MJ, Larson TR, Diderichsen PM, Largajolli A, Hui K, Srimani J, Wang B, Vorog A, Gupta N. Hanley MJ, et al. Clin Transl Sci. 2025 Mar;18(3):e70175. doi: 10.1111/cts.70175. Clin Transl Sci. 2025. PMID: 40025846 Free PMC article. Clinical Trial.
Ponatinib pharmacokinetics (PK) were similar in patients in PhALLCON and patients in a previous population PK analysis. ...Ponatinib exposure was not a significant predictor of arterial occlusive events, venous thromboembolic events, thrombocytopenia, or lipase incr …
Ponatinib pharmacokinetics (PK) were similar in patients in PhALLCON and patients in a previous population PK analysis. ...Ponatin …
Comparison of third-generation tyrosine kinase inhibitor (TKI) ponatinib with first- and second-generation TKIs for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia: A systematic review and bias-corrected meta-analysis.
Raza MZ, Khwaja HF, Arshad HME, Zulnorain, Maqsood M, Nadeem AA, Omais M. Raza MZ, et al. Crit Rev Oncol Hematol. 2025 Sep;213:104806. doi: 10.1016/j.critrevonc.2025.104806. Epub 2025 Jun 13. Crit Rev Oncol Hematol. 2025. PMID: 40517974
Bias correction indicated an 80.2 % lower risk in OS and a 94.2 % lower risk in EFS with ponatinib. Treatment-related adverse events, reported in six studies, showed no significant differences between ponatinib and other TKIs. CONCLUSION: Ponatinib is associa …
Bias correction indicated an 80.2 % lower risk in OS and a 94.2 % lower risk in EFS with ponatinib. Treatment-related adverse events, …
Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib: results from the PhALLCON trial.
Ashaye A, Shi L, Aldoss I, Montesinos P, Vachhani P, Rocha V, Papayannidis C, Leonard JT, Baer MR, Ribera JM, McCloskey J, Wang J, Gao S, Rane D, Guo S. Ashaye A, et al. Leukemia. 2025 Jun;39(6):1342-1350. doi: 10.1038/s41375-025-02608-4. Epub 2025 Apr 16. Leukemia. 2025. PMID: 40240572 Free PMC article. Clinical Trial.
Median time to confirmed improvement was shorter with ponatinib versus imatinib for key measures. Ponatinib-treated patients tended to report being less bothered by treatment side effects as assessed by FACT-GP5. These findings highlight ponatinib's potential …
Median time to confirmed improvement was shorter with ponatinib versus imatinib for key measures. Ponatinib-treated patients t …
Response-Based Dosing for Ponatinib: Model-Based Analyses of the Dose-Ranging OPTIC Study.
Hanley MJ, Diderichsen P, Rich B, Largajolli A, Schindler E, Vorog A, Venkatakrishnan K, Gupta N. Hanley MJ, et al. Clin Pharmacol Ther. 2023 Aug;114(2):413-422. doi: 10.1002/cpt.2956. Epub 2023 Jun 9. Clin Pharmacol Ther. 2023. PMID: 37219378 Clinical Trial.
Optimizing Ponatinib Treatment in CP-CML (OPTIC) was a randomized, phase II dose-optimization trial of ponatinib in chronic phase-chronic myeloid leukemia (CP-CML) resistant to 2 tyrosine kinase inhibitors or with T315I mutation. ...The exposure-response analyses su …
Optimizing Ponatinib Treatment in CP-CML (OPTIC) was a randomized, phase II dose-optimization trial of ponatinib in chronic ph …
Comparative efficacy and safety of different doses of ponatinib versus other tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia: a systematic review and network meta-analysis.
Zhang S, Lai H, Chen H, Wang J, Tu H, Li J. Zhang S, et al. Expert Opin Drug Saf. 2024 Jan;23(1):37-45. doi: 10.1080/14740338.2023.2273339. Epub 2023 Oct 26. Expert Opin Drug Saf. 2024. PMID: 37852954
METHOD: A network meta-analysis (NMA) was conducted by searching randomized controlled trials (RCTs) of ponatinib in patients with CML to compare the efficacy and safety of ponatinib, and ranked under the cumulative ranking curve (SUCRA) to evaluate the optimal trea …
METHOD: A network meta-analysis (NMA) was conducted by searching randomized controlled trials (RCTs) of ponatinib in patients with CM …
36 results